ICD-10 code C11.1: Malignant neoplasm of posterior wall of nasopharynx

Key Takeaways

ICD-10 code C11.1 describes a malignant neoplasm of the posterior wall of the nasopharynx, a site-specific billable diagnosis code.

C11.1 is valid for HIPAA-covered transactions from October 1, 2015 onward and remains current for the 2026 fiscal year.

Coders must distinguish C11.1 from C11.9 (unspecified nasopharynx malignancy): always assign C11.1 when the posterior wall is documented.

Pabau’s claims management software supports accurate ICD-10 code entry, reducing claim denials for oncology and ENT practices.

ICD-10 code C11.1 designates a malignant neoplasm of the posterior wall of the nasopharynx, the surface facing the prevertebral fascia at the back of the upper pharynx. It is a billable, site-specific subcode within the C11 category (malignant neoplasm of nasopharynx) and applies to nasopharyngeal carcinoma confirmed at this subsite.

Assigning C11.1 instead of the unspecified C11.9 requires documentation naming the posterior wall directly, whether from a pathology report, imaging study, or the treating physician’s assessment. That distinction affects claim specificity and how nasopharyngeal carcinoma cases are tracked across oncology and ENT practices.

ICD-10 code C11.1: Clinical description

ICD-10 code C11.1 classifies a malignant neoplasm of the posterior wall of the nasopharynx — a site-specific diagnosis used by oncologists, ENT surgeons, and medical coders to document primary tumors at this anatomical location. Using the unspecified code C11.9 when posterior wall involvement is clearly documented can flag a claim for medical necessity review and delay reimbursement.

The nasopharynx sits at the upper portion of the pharynx, behind the nasal cavity and above the soft palate. Its posterior wall faces the prevertebral fascia. Tumors at this precise subsite account for a meaningful share of all nasopharyngeal carcinoma (NPC) cases and carry distinct staging implications compared with lateral or superior wall lesions.

According to the WHO’s ICD-10 browser, C11.1 sits within the broader category C11, which covers all malignant neoplasms of the nasopharynx, itself nested under C00-C14 (malignant neoplasms of lip, oral cavity, and pharynx).

For practices managing oncology documentation workflows, comparing code selection against the sibling ICD-10 Code C11.3 guide for the anterior nasopharyngeal wall helps ensure consistency across related nasopharynx diagnoses.

Billable status and ICD-10-CM classification of C11.1

C11.1 is a billable and specific ICD-10-CM code. Billable means it can be used directly on claim forms submitted to payers without requiring a more specific subcategory. This is confirmed by both the CDC/NCHS ICD-10-CM web tool and CMS-licensed reference databases. Claims with a service date on or after October 1, 2015 may use C11.1 for HIPAA-covered transactions.

The full ICD-10-CM hierarchy for this code is:

• Chapter: C00-D49 (Neoplasms)
• Block: C00-C14 (Malignant neoplasms of lip, oral cavity and pharynx)
• Category: C11 (Malignant neoplasm of nasopharynx)
• Code: C11.1 (Malignant neoplasm of posterior wall of nasopharynx)

No further specificity is available under C11.1 in the current ICD-10-CM tabular list. It is a terminal code. Laterality designations do not apply to nasopharyngeal wall codes because the anatomical walls are named structures, not paired organs.

This is a common source of coding confusion: coders familiar with paired-organ laterality rules, such as those for kidney or breast cancers, may search for a left/right modifier that simply does not exist for nasopharyngeal wall sites.

Practices that handle oncology billing benefit from claims management software that validates code specificity at the point of entry, preventing submission of parent codes like C11 when a billable subcode such as C11.1 is available.

C11 subcodes: How C11.1 fits within the nasopharynx code family

Understanding where C11.1 sits among its sibling codes helps coders select the right code when the pathology report or operative note specifies a particular nasopharyngeal wall. The full C11 subcode set is:

C11.8 is the appropriate choice when a tumor demonstrably overlaps two or more subsites of the nasopharynx and no single subsite predominates. Do not default to C11.8 as a catch-all; it requires pathological or radiological documentation of overlapping involvement.

When the subsite is genuinely not specified, C11.9 is correct, but coders should query the treating clinician before assigning an unspecified code. For practices managing similar ICD-10 diagnostic code references across specialties, consistent query workflows help reduce unspecified code rates across the board.

Documentation requirements for ICD-10 code C11.1

Accurate assignment of ICD-10 code C11.1 depends on clear source documentation. Coders must be able to point to a specific statement in the medical record that establishes the posterior wall as the primary tumor site. Acceptable documentation sources include:

• Pathology report specifying posterior nasopharyngeal wall as the biopsy site
• Radiology report (CT, MRI, or PET-CT) describing tumor involvement of the posterior wall
• Operative note documenting tumor location during endoscopy or surgical resection
• Attending physician’s clinical assessment or staging note naming the posterior wall subsite

Per the CMS ICD-10-CM guidelines, coders should not infer a diagnosis from diagnostic test results alone without physician confirmation. If a radiology report suggests posterior wall involvement but the treating physician has not documented that finding in their assessment, a clarification query is the appropriate next step before code assignment.

Two additional coding considerations apply to nasopharyngeal malignancies:

• Tobacco use: When the patient has a documented history of tobacco use, ICD-10-CM guidelines instruct coders to assign an additional code from category F17 (nicotine dependence) or Z87.891 (personal history of nicotine dependence) as applicable.
• Alcohol use: Similarly, documented alcohol use disorders should be captured with an additional code from the F10 category when present and clinically relevant.

These “use additional code” conventions reflect ICD-10-CM’s etiology-manifestation framework. Nasopharyngeal carcinoma has a well-established association with Epstein-Barr virus (EBV) exposure, but there is no separate mandatory code for EBV status in the current ICD-10-CM guidelines unless a concurrent active infection is documented.

Maintaining HIPAA-compliant documentation practices for oncology patients ensures that all co-diagnoses are captured and protected appropriately. Digital documentation systems that support structured clinical documentation workflows reduce the risk of missing secondary code opportunities at the time of encounter.

Coders should also watch for secondary hematologic conditions that can accompany nasopharyngeal carcinoma or its treatment, such as sideroblastic anemia due to underlying disease (ICD-10 Code D64.1), which needs an additional code when pathology confirms that specific anemia subtype.

Reviewing the benign neoplasm of nasopharynx coding guide alongside C11.1 also helps coders distinguish malignant from benign nasopharyngeal findings when pathology results are pending or equivocal.

Reduce ICD-10 coding errors with Pabau

Pabau's claims management tools help ENT and oncology practices assign accurate diagnosis codes, track documentation completeness, and submit cleaner claims. See how it works in a live demo.

Book a demo

Sequencing rules and principal diagnosis considerations for C11.1

When a patient presents primarily for treatment of nasopharyngeal carcinoma, C11.1 is the principal diagnosis. The sequencing becomes more nuanced in specific scenarios:

• Metastatic disease: If the patient has developed metastases, the primary site (C11.1) and the metastatic site code are both reported. Sequence them based on the reason for the encounter. If the patient is admitted primarily to treat the primary tumor, C11.1 leads. If the admission is for a complication of metastasis (e.g., spinal cord compression from vertebral metastasis), the appropriate secondary/metastatic code becomes the principal diagnosis. When that admission resolves within the same calendar day, see the CPT Code 99236 guide for same-day observation-to-inpatient billing rules.
• Complications of treatment: When the admission is for chemotherapy or radiation therapy, Z51.11 (encounter for antineoplastic chemotherapy) or Z51.0 (encounter for antineoplastic radiation therapy) is sequenced first, with C11.1 as a secondary diagnosis.
• Personal history after treatment: Once the malignancy is successfully treated and removed, coders transition to Z85.818 (personal history of malignant neoplasm of other sites of lip, oral cavity, and pharynx) or the appropriate Z85.8xx history code for pharyngeal malignancy. ICD-10 code C11.1 would no longer apply as a primary diagnosis once remission is confirmed and treatment has concluded.

These sequencing conventions are governed by the ICD-10-CM Official Guidelines for Coding and Reporting, which the American Health Information Management Association (AHIMA) recommends coding teams review annually as CMS publishes updates each October 1. Practices with multi-specialty workflows benefit from compliance management tools that flag sequencing inconsistencies before claim submission.

Related ICD-10 codes and common crosswalks

Several adjacent codes come up regularly in nasopharyngeal carcinoma coding workflows. Knowing when each applies reduces query volume and prevents claim edits.

• C10 (Malignant neoplasm of oropharynx): The oropharynx sits below the nasopharynx. When a tumor involves both regions, query whether the primary origin is oropharyngeal or nasopharyngeal. C11.1 requires that the posterior wall of the nasopharynx be the documented primary site.
• C11.8 (Overlapping lesion of nasopharynx): Use when pathology or imaging confirms tumor involvement of two or more nasopharyngeal subsites without a single predominant site. Do not assign C11.8 based on clinical impression alone.
• C77.0 (Secondary malignant neoplasm of lymph nodes of head, face, and neck): NPC frequently metastasizes to cervical lymph nodes. C77.0 is assigned alongside C11.1 when nodal involvement is documented, not instead of it.
• Z80.0 (Family history of malignant neoplasm of digestive organs): Not applicable to nasopharyngeal cancer; use Z80.8 (family history of malignant neoplasm of other organs or systems) or Z80.9 if the specific site is unknown.
• Z85.818 (Personal history of malignant neoplasm of other sites of lip, oral cavity, and pharynx): Applicable when the NPC has been treated and the patient is in remission or surveillance. ICD-10 code C11.1 is no longer active once this transition occurs.

Understanding how ICD-10 code C11.1 connects to related codes across the C00-C14 range supports consistency in ICD-10 secondary cancer code documentation workflows across different diagnostic categories within a practice. Secure handling of sensitive oncology diagnoses requires careful attention to patient data security in oncology workflows, particularly when sharing records between treating facilities.

Coders working on related neoplasm encounters may also reference benign neoplasm of lymph nodes coding when distinguishing malignant from benign nodal findings. Patients who develop lymphedema after neck dissection or radiation for nodal disease may also need durable medical equipment coding; see the HCPCS Code E0673 guide for pneumatic compression device billing.

Coding workflow and claim submission

In practice, most coding errors involving C11.1 fall into three categories: using C11.9 when the subsite is documented, assigning C11.8 without documented overlap, and omitting required secondary codes for tobacco or treatment encounters. A structured coding workflow addresses all three.

• Pull the pathology and radiology reports first. Identify the precise anatomical description of the tumor location before opening any coding tool.
• Confirm the reason for the encounter. Treatment encounters, surveillance visits, and complication admissions each follow different sequencing rules.
• Check for documented tobacco use, alcohol use disorders, and active EBV-related conditions that may require additional codes.
• Verify the code against the current fiscal year’s tabular list. ICD-10-CM is updated October 1 annually; codes that were valid in FY2024 may have been revised or deleted by FY2026.

Practices managing oncology documentation at scale benefit from EHR and practice management systems that integrate ICD-10-CM validation at the point of care. Pabau’s clinical record management tools and digital intake forms support structured data capture that feeds accurate diagnosis codes into billing workflows.

This structured capture removes the need for coders to re-extract information from free-text notes, cutting the double-handling that drives most nasopharyngeal coding errors.

Summary

ICD-10 code C11.1 is the correct, billable code when posterior wall involvement is documented — not the unspecified C11.9, which can trigger medical necessity denials. The code is current for FY2026 and requires no further specificity, but it does demand clear source documentation and awareness of sequencing conventions for treatment and metastatic encounters.

For ENT and oncology practices looking to reduce coding errors and submit cleaner claims, Pabau’s practice management platform integrates diagnosis code workflows with clinical documentation from the first patient encounter through post-treatment surveillance.

Practices billing for oncology-adjacent procedures may also benefit from reviewing the subsequent hospital inpatient care billing guide and the chronic care management billing guide for patients with ongoing cancer treatment needs. Book a demo to see how Pabau supports accurate ICD-10 coding at your practice.

Continue your research

Need guidance on related head and neck cancer coding? ICD-10 Code C77.8 guide covers secondary malignant neoplasm coding for multiple lymph node sites, a common companion diagnosis in nasopharyngeal carcinoma with nodal spread.

Need to keep oncology patients engaged between visits? Pabau patient portal software gives patients secure access to appointment scheduling, treatment records, and surveillance visit reminders.

Want to support post-treatment surveillance without extra waiting-room visits? Pabau telehealth software enables remote follow-up consultations from within the same patient record used for in-person visits.

Frequently asked questions